We've found
896
archived clinical trials in
Gastroesophageal Reflux Disease
We've found
896
archived clinical trials in
Gastroesophageal Reflux Disease
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Updated: 1/11/2016
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 1/11/2016
Click here to add this to my saved trials
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Updated: 1/12/2016
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Status: Enrolling
Updated: 1/12/2016
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Updated: 1/12/2016
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Status: Enrolling
Updated: 1/12/2016
Click here to add this to my saved trials
Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.
Updated: 1/12/2016
A Magnetic Resonance Imaging (MRI) Study to Investigate Differences in the Structure and the Function of the Brain at Rest; Between Persons With Functional Pain Conditions Such as IBS or Vulvodynia, IBD and Healthy Controls
Status: Enrolling
Updated: 1/12/2016
Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.
Updated: 1/12/2016
A Magnetic Resonance Imaging (MRI) Study to Investigate Differences in the Structure and the Function of the Brain at Rest; Between Persons With Functional Pain Conditions Such as IBS or Vulvodynia, IBD and Healthy Controls
Status: Enrolling
Updated: 1/12/2016
Click here to add this to my saved trials
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Updated: 1/13/2016
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Status: Enrolling
Updated: 1/13/2016
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Updated: 1/13/2016
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Status: Enrolling
Updated: 1/13/2016
Click here to add this to my saved trials
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Updated: 1/13/2016
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Status: Enrolling
Updated: 1/13/2016
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Updated: 1/13/2016
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Status: Enrolling
Updated: 1/13/2016
Click here to add this to my saved trials
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Updated: 1/13/2016
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Status: Enrolling
Updated: 1/13/2016
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Updated: 1/13/2016
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Status: Enrolling
Updated: 1/13/2016
Click here to add this to my saved trials
Biology in Patients With Reflux Esophagitis
Updated: 1/19/2016
Biology in Patients With Reflux Esophagitis and Mucosal Impedance
Status: Enrolling
Updated: 1/19/2016
Biology in Patients With Reflux Esophagitis
Updated: 1/19/2016
Biology in Patients With Reflux Esophagitis and Mucosal Impedance
Status: Enrolling
Updated: 1/19/2016
Click here to add this to my saved trials
Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
Updated: 1/19/2016
Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
Status: Enrolling
Updated: 1/19/2016
Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
Updated: 1/19/2016
Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
Status: Enrolling
Updated: 1/19/2016
Click here to add this to my saved trials
Can We Predict Who Has Gastroesophageal Reflux Disease (GERD)?
Updated: 1/19/2016
Can We Predict Who Has GERD? Systematic Evaluation of Role of pH Monitoring and the Specific Physiologic pH Parameters in Defining GERD, Bravo, Impedence and SISAP
Status: Enrolling
Updated: 1/19/2016
Can We Predict Who Has Gastroesophageal Reflux Disease (GERD)?
Updated: 1/19/2016
Can We Predict Who Has GERD? Systematic Evaluation of Role of pH Monitoring and the Specific Physiologic pH Parameters in Defining GERD, Bravo, Impedence and SISAP
Status: Enrolling
Updated: 1/19/2016
Click here to add this to my saved trials
Assessment of Esophageal Epithelium Integrity With Mucosal Impedance
Updated: 1/19/2016
Assessment of Esophageal Epithelium Integrity With Mucosal Impedance
Status: Enrolling
Updated: 1/19/2016
Assessment of Esophageal Epithelium Integrity With Mucosal Impedance
Updated: 1/19/2016
Assessment of Esophageal Epithelium Integrity With Mucosal Impedance
Status: Enrolling
Updated: 1/19/2016
Click here to add this to my saved trials
Long-term Outcome of Laparoscopic Hiatal Hernia Repair With or Without Alloderm Mesh at a University Hospital
Updated: 5/10/2016
Long-term Outcome of Laparoscopic Hiatal Hernia Repair With or Without Alloderm Mesh at a University Hospital
Status: Enrolling
Updated: 5/10/2016
Long-term Outcome of Laparoscopic Hiatal Hernia Repair With or Without Alloderm Mesh at a University Hospital
Updated: 5/10/2016
Long-term Outcome of Laparoscopic Hiatal Hernia Repair With or Without Alloderm Mesh at a University Hospital
Status: Enrolling
Updated: 5/10/2016
Click here to add this to my saved trials
Morphological Markers of Gastroesophageal Reflux Disease (GERD)
Updated: 6/29/2016
Dilation of Intercellular Spaces as Morphological Markers of Gastroesophageal Reflux Disease (GERD)In Children
Status: Enrolling
Updated: 6/29/2016
Morphological Markers of Gastroesophageal Reflux Disease (GERD)
Updated: 6/29/2016
Dilation of Intercellular Spaces as Morphological Markers of Gastroesophageal Reflux Disease (GERD)In Children
Status: Enrolling
Updated: 6/29/2016
Click here to add this to my saved trials
Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease
Updated: 7/11/2016
Image-Enhanced Endoscopy for the Diagnosis of Non-Erosive Reflux Disease: A Prospective Case-Control Trial
Status: Enrolling
Updated: 7/11/2016
Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease
Updated: 7/11/2016
Image-Enhanced Endoscopy for the Diagnosis of Non-Erosive Reflux Disease: A Prospective Case-Control Trial
Status: Enrolling
Updated: 7/11/2016
Click here to add this to my saved trials
Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease
Updated: 7/11/2016
Image-Enhanced Endoscopy for the Diagnosis of Non-Erosive Reflux Disease: A Prospective Case-Control Trial
Status: Enrolling
Updated: 7/11/2016
Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease
Updated: 7/11/2016
Image-Enhanced Endoscopy for the Diagnosis of Non-Erosive Reflux Disease: A Prospective Case-Control Trial
Status: Enrolling
Updated: 7/11/2016
Click here to add this to my saved trials
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Updated: 8/15/2016
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Status: Enrolling
Updated: 8/15/2016
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Updated: 8/15/2016
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Status: Enrolling
Updated: 8/15/2016
Click here to add this to my saved trials
Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
Updated: 12/19/2016
Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
Status: Enrolling
Updated: 12/19/2016
Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
Updated: 12/19/2016
Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
Status: Enrolling
Updated: 12/19/2016
Click here to add this to my saved trials
Prospective Randomized Trial Evaluating the Utility of Esophageal Stitches During Laparoscopic Fundoplication
Updated: 1/25/2017
Prospective Randomized Trial Evaluating the Utility of Esophageal Stitches During Laparoscopic Fundoplication.
Status: Enrolling
Updated: 1/25/2017
Prospective Randomized Trial Evaluating the Utility of Esophageal Stitches During Laparoscopic Fundoplication
Updated: 1/25/2017
Prospective Randomized Trial Evaluating the Utility of Esophageal Stitches During Laparoscopic Fundoplication.
Status: Enrolling
Updated: 1/25/2017
Click here to add this to my saved trials
Cough Reflex Sensitivity and Bronchial Hyper-responsiveness
Updated: 2/16/2017
Pilot Studies Evaluating Cough Reflex Sensitivity and Bronchial Hyper-responsiveness: The Road to Cough and Wheeze in Patients With Gastroesophageal Reflux.
Status: Enrolling
Updated: 2/16/2017
Cough Reflex Sensitivity and Bronchial Hyper-responsiveness
Updated: 2/16/2017
Pilot Studies Evaluating Cough Reflex Sensitivity and Bronchial Hyper-responsiveness: The Road to Cough and Wheeze in Patients With Gastroesophageal Reflux.
Status: Enrolling
Updated: 2/16/2017
Click here to add this to my saved trials
Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?
Updated: 3/21/2017
PPI Responsive Esophageal Eosinophilia: GERD or Eosinophilic Esophagitis?
Status: Enrolling
Updated: 3/21/2017
Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?
Updated: 3/21/2017
PPI Responsive Esophageal Eosinophilia: GERD or Eosinophilic Esophagitis?
Status: Enrolling
Updated: 3/21/2017
Click here to add this to my saved trials
Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying
Updated: 5/15/2017
Clinical Applications of Domperidone in Patients With Refractory Gastroesophageal Reflux Disease or Delayed Gastric Solid-Phase Emptying
Status: Enrolling
Updated: 5/15/2017
Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying
Updated: 5/15/2017
Clinical Applications of Domperidone in Patients With Refractory Gastroesophageal Reflux Disease or Delayed Gastric Solid-Phase Emptying
Status: Enrolling
Updated: 5/15/2017
Click here to add this to my saved trials
Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying
Updated: 5/15/2017
Clinical Applications of Domperidone in Patients With Refractory Gastroesophageal Reflux Disease or Delayed Gastric Solid-Phase Emptying
Status: Enrolling
Updated: 5/15/2017
Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying
Updated: 5/15/2017
Clinical Applications of Domperidone in Patients With Refractory Gastroesophageal Reflux Disease or Delayed Gastric Solid-Phase Emptying
Status: Enrolling
Updated: 5/15/2017
Click here to add this to my saved trials
Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying
Updated: 5/15/2017
Clinical Applications of Domperidone in Patients With Refractory Gastroesophageal Reflux Disease or Delayed Gastric Solid-Phase Emptying
Status: Enrolling
Updated: 5/15/2017
Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying
Updated: 5/15/2017
Clinical Applications of Domperidone in Patients With Refractory Gastroesophageal Reflux Disease or Delayed Gastric Solid-Phase Emptying
Status: Enrolling
Updated: 5/15/2017
Click here to add this to my saved trials
Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs
Updated: 9/14/2017
Effect of Polidocanol Endovenous Microfoam (PEM) Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in Venous Leg Ulcers (VLUs)
Status: Enrolling
Updated: 9/14/2017
Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs
Updated: 9/14/2017
Effect of Polidocanol Endovenous Microfoam (PEM) Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in Venous Leg Ulcers (VLUs)
Status: Enrolling
Updated: 9/14/2017
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD
Updated: 9/25/2017
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials